
After the midterms, biopharma needs more than a policy forecast
A Democratic Congress will likely sharpen oversight of the FDA and drug pricing, but the most consequential choices for drug developers in 2027 will still be made in clinical trial protocols, financing plans and portfolio reviews. Washington has had a leadership change, but the development equation has not. The November… Read More












